ajmaline and Myocardial-Infarction

The aim of this study was to determine whether an antiarrhythmic, Ajmaline, could have proarrhythmic effects on the atrium and to compare the results with those of other antiarrhythmic drugs. A total of 1950 patients without cardiac failure or recent (less than 6 weeks) myocardial infarction were given 1 mg/kg of Ajmaline intravenously during electrophysiological investigation. A proarrhythmic effect was defined as the occurrence of supraventricular tachycardia (SVT) in a patient without this arrhythmia before the test or the facilitation of its induction. Fifty five patients developed SVT (mainly atrial tachyarrhythmias: 48 cases, and some junctional tachycardia: 7 cases) which occurred spontaneously in 22 patients and during fixed atrial pacing in 33 patients. Fifteen patients developed ventricular tachycardia (VT). The predisposing factors for the development of SVT were: a previous history suggesting spontaneous SVT (28 patients; 51 p. 100); sinoatrial block (14 patients--the only abnormality in 10 cases). Seventeen patients had none of these factors but 8 had known cardiac pathology and the other 9 were relatively elderly patients (79 years). Twelve of the patients developing VT had known cardiac disease, bundle branch block in 12 cases and previous VT in 6 cases. In conclusion, proarrhythmic effects of Ajmaline are infrequent if its contraindications are respected, but they do exist at both atrial (2.8 p. 100) and ventricular levels (0.8 p. 100): the risk factors are comparable: previous spontaneous arrhythmias or ECG changes (SA block at the atrial and bundle branch block at the ventricular level).

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ajmaline; Anti-Arrhythmia Agents; Coronary Disease; Electric Stimulation; Electrocardiography; Female; Heart Atria; Humans; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Tachycardia, Supraventricular

Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrioventricular Node; Diagnosis, Differential; Electrocardiography; Humans; Lidocaine; Myocardial Infarction; Procainamide; Quinidine; Verapamil; Wolff-Parkinson-White Syndrome

The more recent antiarrhythmic drugs sometimes with more complex action extend the therapeutic possibilities. In addition, numerous other substances are in clinical trial. An ideal antiarrhythmic agent with a reliable action, persistent effective levels, easily absorbable and with few side effects is not found among them. The indication for therapy in ventricular extrasystole is made on the grounds of an ominous ECG criteria and a presumed clinical threat. Controversial results of lidocaine therapy of acute mayocardial infarction are possibly due to pharmacokinetic factors. For "inhomogeneous repolarization" with increased tendency to ventricular fibrillation inducing drugs should be avoided. Malignant cardiac rhythm irregularities possible leading to sudden death require systemic therapeutical testing. In this case, combinations of antiarrhythmic drugs have the highest effectiveness.

Topics: Action Potentials; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Bretylium Compounds; Calcium; Cardiac Complexes, Premature; Digoxin; Disopyramide; Electrophysiology; Humans; Lidocaine; Mexiletine; Myocardial Infarction; Phenytoin; Quinidine; Tachycardia; Tachycardia, Paroxysmal; Verapamil

Topics: Adult; Aged; Ajmaline; Animals; Arrhythmias, Cardiac; Atropine; Bretylium Compounds; Cardiac Complexes, Premature; Coronary Care Units; Dogs; Electrocardiography; Female; Heart Block; Humans; Isoproterenol; Lidocaine; Male; Myocardial Infarction; Pacemaker, Artificial; Phenytoin; Procainamide; Quinidine; Tachycardia; Ventricular Fibrillation

Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Female; Humans; Injections; Lidocaine; Male; Middle Aged; Myocardial Infarction; Procainamide; Quinidine

In 35 patients with acute myocardial infarction premature ventricular complexes were quantified from stored continuous electrocardiographic tape recordings using a semiautomated arrhythmia detection system. Seventeen patients, separated at random, received no antiarrhythmic drug and formed the control group. In nine patients prajmalium bitartrate was given orally at a dose of 60 mg. (20 mg. every 4 hours). Nine patients had permanent infusions of 2.1 mg./minute lidocaine (corresponding to a daily dose of 3 g.). In both treated groups premature ventricular complexes decreased significantly as compared to the spontaneous frequency in the control group. Six hours after the onset of therapy premature ventricular complexes were reduced to 37% of the initial value in the prajmalium bitartrate group and to 51% in the lidocaine group, whereas in the control group frequency increased (169%). The peak effect was reached after ten hours when premature ventricular complexes were reduced to 5% under prajmalium bitartrate and to 20% under lidocaine administration. Runs of premature ventricular complexes were nearly completely suppressed after administration of prajmalium bitartrate. Under lidocaine administration runs were moderately and not significantly reduced. Eight hours after the onset of therapy, runs were reduced to 8% of the initial value under prajmalium bitartrate and to only 79% under lidocaine. The effect of prajmalium bitartrate on runs of premature ventricular complexes was significantly more pronounced than the effect of lidocaine. The present study documents that orally administered prajmalium bitartrate is an alternative to intravenous administration of lidocaine in the treatment of ventricular arrhythmias after acute myocardial infarction.

Topics: Administration, Oral; Ajmaline; Anti-Arrhythmia Agents; Heart Ventricles; Humans; Injections, Intravenous; Lidocaine; Middle Aged; Myocardial Infarction; Prajmaline; Time Factors

Topics: Adult; Aged; Ajmaline; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Clinical Trials as Topic; Drug Evaluation; Heart Ventricles; Humans; Middle Aged; Myocardial Infarction; Procainamide; Quaternary Ammonium Compounds; Time Factors

Topics: Adult; Aged; Ajmaline; Cardiac Complexes, Premature; Clinical Trials as Topic; Electrocardiography; Female; Humans; Male; Mexiletine; Middle Aged; Myocardial Infarction; Propylamines

Topics: Administration, Oral; Ajmaline; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Humans; Injections, Intravenous; Lidocaine; Middle Aged; Myocardial Infarction; Time Factors

Haemodynamic changes after single intravenous injection of antiarhythmic doses of ajmaline (50 mg) and lidocain (100 mg) were measured comparatively in 10 patients with acute myocardial infarction, stable cardiac rhythm and without manifest left heart failure. The effects of ajmaline were characterized by a significant decrease of systolic arterial pressure (9%), of left ventricular stroke work index (15%) as well as by an increase of the mean pressure of the pulmonary artery (7%) in the early phase after application. No significant changes in cardiac index, stroke volume index, systemic vascular resistance, right and left ventricular filling pressures and heart rate occurred. The effects of lidocain on the cardiac circulation were comparatively small. The intravenous administration of lidocain did not result in significant changes of the cardiac index or left and right ventricular filling pressures. Diastolic arterial pressure increased significantly (5%), while the heart rate decreased (5%).

Topics: Ajmaline; Blood Pressure; Cardiac Output; Coronary Circulation; Heart Rate; Hemodynamics; Humans; Lidocaine; Myocardial Infarction

Topics: Administration, Oral; Ajmaline; Cardiac Complexes, Premature; Drug Evaluation; Electrocardiography; Heart Ventricles; Humans; Lidocaine; Myocardial Infarction; Time Factors

Topics: Adult; Ajmaline; Angina Pectoris; Clinical Trials as Topic; Diagnosis, Differential; Electric Countershock; Female; Heart Arrest; Humans; Intensive Care Units; Lidocaine; Male; Middle Aged; Monitoring, Physiologic; Myocardial Infarction; Pacemaker, Artificial; Prognosis; Propranolol; Resuscitation; Ventricular Fibrillation

Topics: Acute Disease; Adult; Aged; Ajmaline; Aminocaproates; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Heart; Heart Block; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Rupture; Shock, Cardiogenic

We report a 37-year-old man with documented aborted sudden death. After resuscitation, the patient showed no structural heart disease but the ECG showed a right bundle-branch block with a descending ST segment elevation in leads V(1) and V(2). After transient normalization of the ECG, the administration of ajmaline led to spontaneous development of the distinct descending ST segment elevation in the right precordial leads and therefore to the diagnosis of Brugada syndrome. The incidence of sudden cardiac death among these patients is high. The only treatment is an implantable cardioverter-defibrillator (ICD). The Brugada syndrome should therefore be borne in mind in the differential diagnosis of sudden death.

Topics: Adult; Ajmaline; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Diagnosis, Differential; Electrocardiography; Humans; Male; Myocardial Infarction; Resuscitation

A case of 52 years old male patient with antero-septal myocardial infarction in the course of type B Wolff-Parkinson-White syndrome has been described. Intravenous administration of 50 mg of ajmaline 2 hours after admission to hospital suppressed the electrocardiographic signs of preexcitation and disclosed previously imperceptible image of acute inferior myocardial infarction. Repeated intravenous ajmaline injection before discharging from the hospital enabled to specify the final localisation of the infarction (antero-septal and inferior), made possible the realization of ecg exercise test and ventricular late potentials analysis (no late potentials were detected). The clinical course of the disease was complicated by the left ventricular failure, which was brought in check without digitalis administration. The outpatient follow-up is carried out after the health resort treatment and the patient is in good conditions 6 months after his discharge from the hospital. There is no such a case found in the available literature.

Topics: Ajmaline; Electroencephalography; Exercise Test; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Wolff-Parkinson-White Syndrome

As yet the antiarrhythmic efficacy of ajmaline with regard to suppressing the induction of sustained ventricular tachycardia after myocardial infarction has not been determined. Therefore, programmed electrical stimulation was performed in 8 conscious, chronically instrumented mongrel dogs 8-20 days after a 4-hour occlusion of the left anterior descending coronary artery. At baseline all animals responded with sustained ventricular tachycardia. Thereafter, ajmaline was administered at two consecutive i.v. doses: a bolus of 0.7 mg kg-1 followed by infusion of 2 mg kg-1 h-1 and infusion of 4 mg kg-1 h-1. The induction of sustained ventricular tachycardia was prevented in 2/8 animals by 2 mg kg-1 h-1 ajmaline and in 1/8 animals by 4 mg kg-1 h-1 ajmaline. During sinus rhythm only 4 mg kg-1 h-1 ajmaline significantly increased QRS-duration and intraventricular activation times, but during rapid right ventricular pacing (cycle length = 330 ms) both doses of ajmaline increased QRS duration and intraventricular conduction times. 4 mg kg-1 h-1 ajmaline also increased the cycle length of induced sustained ventricular tachycardia. In 3 animals induction of sustained ventricular tachycardia during infusion of 4 mg kg-1 h-1 ajmaline was achieved by introduction of less extrastimuli than at baseline. Furthermore the coupling intervals of extrastimuli that induced sustained ventricular tachycardia were substantially prolonged by this dose. Inhomogeneity of conduction between left ventricular normal zone and left ventricular infarct zone was significantly increased by 4 mg kg-1 h-1 ajmaline during rapid right ventricular pacing, but not during sinus rhythm.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Ajmaline; Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Coronary Vessels; Dogs; Electric Stimulation; Electrophysiology; Female; Heart Conduction System; Male; Myocardial Infarction; Myocardial Reperfusion; Tachycardia, Ventricular

Topics: Ajmaline; Arrhythmias, Cardiac; Drug Resistance; Humans; Lidocaine; Myocardial Infarction; Thrombolytic Therapy

Up to now lidocain was regarded as remedy of first choice in life-threatening ventricular arrhythmias. According to more recent investigations in the emergency situation ajmalin showed itself superior to lidocain in the treatment of ventricular tachycardias. For the prophylaxis of primary ventricular fibrillation lidocain is still recommended, though despite numerous studies an effectiveness is not verified. The treatment of the primary ventricular fibrillation should always be performed by defibrillation as far as possible. The earlier it is performed the more successful is the measure. If a defibrillator is not at disposal an attempt with lidocain or ajmalin can bie made.

Topics: Ajmaline; Combined Modality Therapy; Electric Countershock; Electrocardiography; Emergencies; Heart Ventricles; Humans; Lidocaine; Myocardial Infarction; Tachycardia; Ventricular Fibrillation

The effects of prajmalium bromide on normal and abnormal automaticity were studied in Purkinje fibers from dog hearts at late stages of experimental myocardial infarction. Prajmalium bromide (1.2 micromol/l) moderately reduced the frequency of normal and abnormal automaticity by 16 and 20% respectively. Prajmalium bromide induced early after-depolarizations, increased the frequency of spontaneous firing and decreased the maximum diastolic potential in the fibers that initially developed the automaticity of an intermediate type between normal and abnormal. It is suggested that antiarrhythmic effects of prajmalium bromide in the late stage of experimental myocardial infarction are not related to the influence of the drug on the abnormal automaticity in Purkinje fibers.

Topics: Action Potentials; Ajmaline; Animals; Culture Media; Diastole; Dogs; Dose-Response Relationship, Drug; Heart Conduction System; In Vitro Techniques; Myocardial Contraction; Myocardial Infarction; Prajmaline; Purkinje Fibers; Time Factors

Topics: Aged; Ajmaline; Cardiac Complexes, Premature; Humans; Jaundice; Male; Myocardial Infarction; Prajmaline

Clinical safety and hemodynamic repercussions were studied after administration of six class I antiarrhythmics (xylocaine, ajmaline, mexiletine, lorcainide, indecainide and tocainide) to patients presenting acute myocardial infarction without complications. The hemodynamic parameters monitored generally followed the same trends. A significant decrease of more than 10 per cent of the initial value was seen in systolic blood flow after injection of lorcainide, indecainide and tocainide. Peripheral vascular resistance increased moderately. Pulmonary capillary pressure increased by more than 40 per cent of the starting value after administration of mexiletine, indecainide and tocainide (significant increase in case of mexiletine). These changes in patients presenting infarction without complications are not of clinical importance. There were, however, two very severe cases of hemodynamic reaction after administration of mexiletine. Other signs of intolerance were seen, but they were of minor importance and administration of the drugs was not interrupted. Xylocaine and ajmaline produced the smallest depression of left ventricular functional activity in these patients.

Topics: Ajmaline; Anti-Arrhythmia Agents; Benzeneacetamides; Fluorenes; Hemodynamics; Lidocaine; Mexiletine; Myocardial Infarction; Piperidines; Tocainide

Topics: Adult; Ajmaline; Diagnosis, Differential; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Vectorcardiography; Wolff-Parkinson-White Syndrome

Forty-three patients in the acute phase of myocardial infarction who were resistant to conventional doses of lidocaine received Ajmaline intravenously (50 mg bolus followed by constant infusion rate of 1-1.5 mg/min). Dangerous ventricular arrhythmias were abolished in 72% of this group of patients (group A). In the remaining patients (28%), Ajmaline was found to be ineffective (group B). There was no reduction of systolic or diastolic blood pressure and there was an insignificant increase in heart rate. Atrio-ventricular or intraventricular conduction defects appeared in 46% of the patients described. There was a statistically significant increase in occurrence of heart blocks in group B patients and among these complete left bundle branch block (CLBBB) was the most prevalent. Atrio-ventricular or intraventricular conduction defects were transient, appearing between 8-36 h (mean 23 h), and were not accompanied by reduction of ventricular rate. Conduction defects disappeared within several hours (up to 24 hours) after Ajmaline was discontinued. It is concluded that Ajmaline administered by this regimen is an effective alternative agent for patients with ventricular arrhythmia not controlled by lidocaine in the acute phase of myocardial infarction.

Topics: Ajmaline; Cardiac Complexes, Premature; Digoxin; Heart Conduction System; Heart Failure; Humans; Lidocaine; Myocardial Infarction; Time Factors; Ventricular Fibrillation

Topics: Aged; Ajmaline; Cardiac Complexes, Premature; Drug Evaluation; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prajmaline

Nine cases of major ventricular arrhythmia (tachycardia (VT), fibrillation (VF), torsades de pointe) are reported in patients with sequellae of myocardial infarction but without residual angina or cardiac failure. --Six of these disturbances of excitability occurred after a bradycardia due to sino atrial block (SAB) which favoured the breakthrough of abnormal automatic foci. This form of the bradycardia-tachycardia syndrome was demonstrated by endocavitary electrophysiological exploration.. These were the only cases of major ventricular arrhythmia observed in a series of 88 SABs. Reputedly benign, they illustrate the potential gravity of a conduction defect in patients with sequellae of myocardial infarction. --Three other cases of abnormal ventricular excitability complicating the administration of 1 mg/kg of Ajmaline to test for paroxysmal block after myocardial infarction. These were the only cases of VT observed in a series of 800 Ajmaline tests. The three patients have had no further episodes of VT after 1 year's follow-up. On the other hand, in 43 Ajmaline tests without VT in patients with myocardial infarction, 6 cases of VT and 1 lethal VF were later observed. This demonstrates the lack of significance of episodes of VT during Ajmaline tests, the depressant action of the drug on intracardiac conduction favouring the initiation of reentry. In conclusion, a history of myocardial infarction exposes the patient to the risk of major ventricular arrhythmias in SAB, the detection of which should indicate pacemaker therapy from the first symptoms. The use of an intravenous antiarrhythmic agent should be avoided as it may aggravate arrhythmias. However, the arrhythmia is of no prognostic significance.

Topics: Aged; Ajmaline; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Block; Humans; Male; Myocardial Infarction; Prognosis; Sinoatrial Block

Seven patients with right precordial Q waves (RPQs) simulating anterior myocardial infarction (MI), but without a previous history of either MI or other underlying diseases showing RPQ, were injected intravenously with ajmaline. The RPQs were abolished in 5 patients. Two patients displayed a transient, spontaneous abolition of RPQ, and 2 patients had false positive ST responses to the exercise test. Ajmaline injection in patients with documented MI and in patients with normal electrocardiograms did not produce any notable changes in the initial part of QRS complex. The RPQs abolished by ajmaline were probably a result of a mild pre-excitation, induced by Mahaim fiber conduction, because the PR and QRS intervals were normal and low amplitude delta waves were found in some patients. It is important to note that altered intraventricular conduction, probably a mild preexcitation, can markedly deform electrocardiograms and mimic myocardial infarction.

Topics: Adult; Ajmaline; Electrocardiography; False Positive Reactions; Female; Humans; Male; Middle Aged; Myocardial Infarction; Physical Exertion

The present study was designed to assess the antiarrhythmic Prajmalium Bitartrate (PB) efficacy in the long term treatment of 22 patients with recent myocardial infarction and persistent, frequent, polimorphous, repetitive (two or more in a row) ventricular premature complexes (VPCs). VPCs were exposed by means of 24-hours ambulatory monitoring. The acute drug testing with a single dose of PB (30 mg) was followed by multiple maintenance therapy with a dose decreasing from 60 to 40 mg every day. Than, the long term antiarrhythmic action was evaluated by both monitoring and exercise stress testing (EST), symptom self-limited, in a 7 months and 28 days follow-up. A favorable therapeutic effect, with a reduction of VPCs frequency greater than 85% and the suppression of their greater Lown degrees, was obtained in 13 cases (59.2%) using PB alone and in 6 cases (27.2%) using PB associated with Amiodarone in 5 patients and with Metoprololo in one. No VPCs were present or they were less than 2 every 3 minutes during EST. Fourteen patients reported a recurrence of VPCs when the drug was stopped for 24-28 hours, after 3-5 months of the treatment. In 3 patients (13.6%) the PB was uneffective. In a case there was, during the acute drug testing, a paradox increasing of the arrhythmias, and in the other two an abnormal lengthening of QTc interval, while arrhythmia was unchanged. PB, alone or associated with other antiarrhythmic drugs, appears a well tolerated, handy and effective agent and it can be proposed as a drug of first choice for controlling VPCs.

Topics: Adult; Aged; Ajmaline; Ambulatory Care; Amiodarone; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Metoprolol; Middle Aged; Monitoring, Physiologic; Myocardial Infarction; Prajmaline

Topics: Administration, Oral; Ajmaline; Humans; Injections, Intravenous; Lidocaine; Myocardial Infarction

Topics: Acetanilides; Adult; Aged; Ajmaline; Humans; Lidocaine; Middle Aged; Myocardial Contraction; Myocardial Infarction; Systole; Trimecaine

Topics: Ajmaline; Humans; Lidocaine; Myocardial Infarction

Topics: Action Potentials; Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Calcium; Disopyramide; Electrophysiology; Humans; Lidocaine; Mexiletine; Myocardial Infarction; Phenytoin; Procainamide; Quinidine; Tachycardia; Verapamil

Topics: Aged; Agranulocytosis; Ajmaline; Female; Humans; Myocardial Infarction

Of 335 consecutive patients (pts) admitted to the coronary care unit (CCU) for acute myocardial infarction (AMI), 34 (10%) evidenced complete heart block (HB). The overall inhospital mortality was 14% (47 pts) versus 39% of the HB group (13 pts). No previous conduction disturbances were documented in 58% of pts before appearance of complete HB. Complete HB was preceded in 52% of pts by first or second degree HB or bundle branch block. Of 21 pts with HB discharged from the hospital, 5 (23%) died between 5 and 24 months (mean 12): no patients had sudden death; 16 pts (76%) are still alive after 13 to 45 months (mean 30). His bundle electrophysiologic (HBE) study was performed in 10 pts of the HB group after 4 to 40 months: 4 pts with anterior versus 6 with inferior AMI. Conduction disturbances were no longer present in all but one pt who had H-V 60 msec. Ajmaline (50 + 50 mg iv) prolonged A-H over 130 msec in 4 pts; H-V was not significantly increased in 8 of the 10 pts, while in two pts was 100 msec. One pt in the acute phase and one pt 12 months later, required pacemaker (PM) implant (both had inferior MI).. no sudden death was documented during the follow-up period. The late HBE study, before and after ajmaline, did not allow to recognize critical conduction abnormalities suggessting prophylactic PM implantation.

Topics: Adult; Aged; Ajmaline; Cardiac Pacing, Artificial; Female; Follow-Up Studies; Heart Block; Humans; Male; Middle Aged; Myocardial Infarction; Pacemaker, Artificial

Topics: Ajmaline; Diagnosis, Differential; Female; Humans; Middle Aged; Myocardial Infarction; Vectorcardiography; Wolff-Parkinson-White Syndrome

Topics: Ajmaline; Arrhythmias, Cardiac; Myocardial Infarction

For the practicing physician the medicamentous treatment of the patients with infarction is the main problem of the secondary prevention in the prehospital phase as well as in the after-treatment. In these cases in the acute phase not the myocardial insufficiency is in the centre of the out-patient care, but the therapy of the disturbances of cardiac rhythm, which mainly cause the high lethality in the early phase. Therefore, uncomplicated infarctions, in whch care must be taken only for a sedation of sympathico-adrenergic reactions and a volume reduction of the heart, should be differed from complicated cases. However, an immediate transport to the hospital must be guaranteed. If there appear a contraction insufficiency of the left ventricle or threatening disturbances of the rhythm, additionally glycosides and saluretics must be administered as well as an aimed antiarrhythmic therapy must be initiated. The necessary medicamentous measures are described dependent upon the diagnosis of brady- and tachycardiac disturbances of the rhythm. The author enters briefly the problems of volume substitution, treatment of acidosis as well as the administration of beta-sympathicolytics and gluco-corticoids. - In the after-treatment of infarctions anticoagulants are the only medicaments to be prescribed, when findings completely without complications are present. If, however, there are signs of activity of the coronary heart disease in the post-infarction phase, a basic therapy with a glycoside and anticoagulants as well as an individually to be varied additive therapy with nitro-preparations, beta-sympathicolytics, saluretics, anti-hypertensive agents and antiarrhythmic agents are necessary.

Topics: Acidosis; Adrenergic beta-Antagonists; Aftercare; Ajmaline; Ambulatory Care; Anticoagulants; Arrhythmias, Cardiac; Atropine; Cardiac Complexes, Premature; Cardiac Glycosides; Glucocorticoids; Heart Block; Heart Failure; Hospitalization; Humans; Lidocaine; Meperidine; Metaproterenol; Morphine; Myocardial Infarction; Nitroglycerin; Tachycardia

Topics: Ajmaline; Angina Pectoris; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Heart Conduction System; Heart Ventricles; Humans; Lidocaine; Myocardial Infarction; Procainamide; Quinidine

Topics: Ajmaline; Anti-Arrhythmia Agents; Aprindine; Arrhythmia, Sinus; Arrhythmias, Cardiac; Bradycardia; Humans; Isoproterenol; Lidocaine; Myocardial Infarction; Pacemaker, Artificial; Phenytoin; Procainamide; Propranolol; Quinidine; Tachycardia; Verapamil

Topics: Administration, Oral; Ajmaline; Aniline Compounds; Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Diethylamines; Disopyramide; Dogs; Heart Ventricles; Humans; Indans; Injections; Injections, Intravenous; Myocardial Infarction; Practolol; Procainamide; Propranolol; Quinidine; Tachycardia

Topics: Acute Disease; Adult; Aged; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Carbamates; Coronary Disease; Drug Resistance; Electrocardiography; Female; Heart Rate; Heart Ventricles; Humans; Hypertension; Infusions, Parenteral; Lidocaine; Male; Middle Aged; Myocardial Infarction; Phenytoin; Procainamide; Quaternary Ammonium Compounds; Quinidine; Tachycardia

Topics: Administration, Oral; Adult; Aged; Ajmaline; Arrhythmias, Cardiac; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Lidocaine; Male; Middle Aged; Myocardial Infarction; Procainamide; Propranolol; Quinidine

Topics: Adrenergic beta-Antagonists; Ajmaline; Arrhythmias, Cardiac; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Phenytoin; Procainamide; Quinidine

Topics: Aged; Ajmaline; Cardiac Catheterization; Electric Countershock; Electrocardiography; Female; Heart Atria; Heart Conduction System; Heart Ventricles; Humans; Myocardial Infarction; Tachycardia

Topics: Acute Disease; Adult; Aged; Ajmaline; Cardiac Output; Central Venous Pressure; Heart Rate; Humans; Lidocaine; Male; Middle Aged; Myocardial Infarction; Vascular Resistance

Topics: Ajmaline; Arrhythmias, Cardiac; Drug Tolerance; Hemodynamics; Humans; Lidocaine; Myocardial Infarction; Phytotherapy; Plants, Medicinal; Rauwolfia

Topics: Adult; Ajmaline; Blood Pressure; Heart; Heart Defects, Congenital; Heart Valve Diseases; Hemodynamics; Humans; Middle Aged; Myocardial Infarction; Phytotherapy; Plants, Medicinal; Rauwolfia

Topics: Aged; Ajmaline; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Block; Humans; Lidocaine; Male; Middle Aged; Myocardial Infarction; Phytotherapy; Plants, Medicinal; Procainamide; Quinidine; Rauwolfia

Topics: Adult; Aged; Ajmaline; Arrhythmias, Cardiac; Electric Countershock; Female; Humans; Lidocaine; Male; Middle Aged; Myocardial Infarction; Pacemaker, Artificial; Procainamide; Ventricular Fibrillation

Topics: Ajmaline; Drug Therapy; Electrocardiography; Humans; Myocardial Infarction; Rauwolfia; Tachycardia; Tachycardia, Ventricular

Topics: Ajmaline; Myocardial Infarction; Rauwolfia; Tachycardia; Tachycardia, Paroxysmal; Tachycardia, Ventricular